A3P Biomedical
Camilla Eriksson has extensive experience in the biomedical field, currently serving as Director of Lab Techniques and Methods at A3P Biomedical since February 2022, after previously holding positions as Senior Scientist and Manager in the same department. Prior to A3P, Camilla worked at Atlas Antibodies as a Project Leader where responsibilities included antibody development and process improvements. Experience also includes roles at Nordic BioSite as a Project Leader for histology services and IVD antibodies, and several key positions at Thermo Fisher Scientific focused on product development and biomarker analysis. Camilla's career began at Pharmacia Diagnostics and Pharmacia & Upjohn Diagnostics, where early work centered on immunoassay development and antibody production. Camilla holds a Master of Science in Biochemistry, Immunology, and Molecular Biology from Uppsala University and completed a Mentorship Program in Leadership from 2016 to 2018.
This person is not in any teams
This person is not in any offices
A3P Biomedical
1 followers
A3P Biomedical provides prostate cancer diagnosis and treatment. They specialize in advanced prostate cancer diagnostics. Their main product, Stockholm3, is a clinically and commercially validated blood test for the early detection of aggressive prostate cancer. The test combines protein markers, genetic markers, and clinical data in a proprietaryalgorithm for the purpose of detecting aggressive prostate cancer at an early stage.